UNSPSC 51411806: Fenoxedil hydrochloride

This classification denotes a vasodilating agent with the molecular formula C28H42N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1056JI5L58, chemically known as acetamide, 2-(4-butoxyphenoxy)-n-(2,5-diethoxyphenyl)-n-(2-(diethylamino)ethyl)-, hydrochloride (1:1), but more generally known as fenoxedil hydrochloride, which bears US NIH Compound Identifier 119645. European Medicines Agency schedules fenoxedil hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07582MIG.

Most nations, for tariff purposes, schedule fenoxedil hydrochloride under HS 29242995. SMILES: CCCCOC1CCC(CC1)OCC(=O)N(CCN(CC)CC)C2CC(CCC2OCC)OCC.CL.

UNSPSC 51411806 Fenoxedil hydrochloride, a Commodity code, captures emergency and critical-care pharmaceutical supplies procured by state and local health agencies, fire and rescue departments, and multistate cooperative purchasing alliances. State and local governments buy specific injectable medications under this code to support advanced life support (ALS) operations, hospital formularies, and pharmacy benefit programs. Issuing bodies include municipal fire rescue departments (Tampa Fire Rescue), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance). The work involves competitive solicitation of pharmaceutical manufacturers and authorized distributors to supply controlled-quantity, time-sensitive medications with strict expiration and quality-assurance requirements, often with delivery windows of ten calendar days or less and warranty obligations extending twelve months post-delivery.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Solicitation 26P00188) on April 24, 2026 for advanced life support medications—Labetalol, Epinephrine, Adenosine, and Diltiazem in specific quantities—with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer pharmacy benefit programs, signaling future formal procurement activity. The Minnesota Department of Administration's Office of State Procurement, administering the multistate MMCAP cooperative, issued an RFP (S1070000015802) posted January 20, 2026 with a response deadline of March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers, with awards effective July 1, 2026 and a two-year contract term. Vendors to MMCAP must carry comprehensive insurance, certify cGMP and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee on all contract purchases.